Valuation: Fulgent Genetics, Inc.

Market Cap 592M 518M 476M 443M 841M 56.38B 854M 5.71B 2.22B 27.71B 2.22B 2.17B 95.5B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 592M 518M 476M 443M 841M 56.38B 854M 5.71B 2.22B 27.71B 2.22B 2.17B 95.5B EV / Sales 2026 *
1.68x
EV / Sales 2027 * 1.47x
Free-Float
52.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week+4.46%
Current month+1.61%
1 month+14.94%
3 months+23.96%
6 months-18.52%
Current year-20.63%
1 week 19.68
Extreme 19.68
21.19
1 month 17.64
Extreme 17.64
21.19
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
44.09
5 years 13.46
Extreme 13.46
112
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 2022-05-02
Chief Executive Officer 70 2016-05-12
Director of Finance/CFO 58 2015-12-31
Director TitleAgeSince
Chairman 70 2016-08-31
Director/Board Member 76 2019-07-31
Director/Board Member 67 2023-01-02
Date Insider Type Main position Quantity % Market Cap.
06-01Sell

Chief Technology Officer

-1,688 0.0055%
06-01Sell

Founder

-2,146 0.0070%
05-31Tax

Chief Financial Officer

-2,087 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+4.46%+3.94%-42.80% 592M
+1.10%+6.65%+72.68%+472.96% 40B
+1.09%+5.71%+9.58%+37.36% 23.53B
+1.58%+4.06%-20.86%-40.58% 7.28B
+4.77%+13.19%+22.33%+117.22% 5.41B
-0.28%-2.58%+19.40%+46.08% 2.89B
-5.86%-3.31%-26.31%+1,042.30% 2B
+1.27%+6.99%+100.79%-3.93% 1.97B
-0.44%+7.04%+38.02%-22.20% 1.82B
+2.08%+0.70%+22.24%-3.56% 1.65B
Average +0.54%+5.12%+24.18%+160.29% 8.72B
Weighted average by Cap. +1.14%+6.86%+39.15%+255.64%

Financials

2026 *2027 *
Net sales 352M 308M 283M 264M 500M 33.53B 508M 3.4B 1.32B 16.48B 1.32B 1.29B 56.8B 402M 351M 323M 301M 571M 38.25B 579M 3.87B 1.51B 18.8B 1.51B 1.48B 64.79B
Net income -90M -78.68M -72.31M -67.4M -128M -8.57B -130M -868M -337M -4.21B -338M -331M -14.52B -73M -63.82M -58.65M -54.67M -104M -6.95B -105M -704M -274M -3.42B -274M -268M -11.77B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
26-07-02 US$20.85 +0.14% 184,527
26-07-01 US$20.82 +1.46% 307,457
26-06-30 US$20.52 -0.05% 251,706
26-06-29 US$20.53 +2.86% 294,593
26-06-26 US$19.96 +2.67% 505,913
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.85USD
Average target price
15.00USD
Spread / Average Target
-28.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock